Detalhe da pesquisa
1.
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
BMC Ophthalmol;
23(1): 443, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37919692
2.
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.
J Drugs Dermatol;
22(8): 754-760, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37556515
3.
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
J Drugs Dermatol;
12(8): 874-80, 2013 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23986160
4.
Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis.
J Dermatolog Treat;
34(1): 2200872, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37166385
5.
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
Cancer Med;
12(3): 2378-2388, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35880244
6.
Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.
BMC Dermatol;
12: 10, 2012 Jul 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22831458
7.
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
J Drugs Dermatol;
11(8): 943-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22859239
8.
Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Value Health;
14(5): 652-6, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21839402
9.
Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis.
J Drugs Dermatol;
10(8): 843-50, 2011 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21818505
10.
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
J Am Acad Dermatol;
63(3): 457-65, 2010 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20462664
11.
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
Leuk Lymphoma;
48(1): 46-55, 2007 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17325847
12.
A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis.
J Dermatolog Treat;
27(1): 19-26, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26138406
13.
Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
Int J Cardiol;
100(2): 253-65, 2005 Apr 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15823633
14.
Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis.
J Dermatolog Treat;
26(2): 113-20, 2015 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24552612
15.
Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
J Dermatolog Treat;
24(5): 351-5, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22632451
16.
Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2â/â3 trial.
J Dermatol;
39(9): 761-9, 2012 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22409383
17.
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Ann N Y Acad Sci;
1263: 1-12, 2012 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22823582
18.
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
J Dermatolog Treat;
22(3): 138-43, 2011 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21254886
19.
The value to patients of reducing lesion severity in plaque psoriasis.
J Dermatolog Treat;
22(5): 266-75, 2011 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21781015
20.
Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
J Dermatolog Treat;
22(6): 337-47, 2011 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21034290